Hauke RJ, Tarantolo SR. Hematopoietic growth factors. Lab Med 2000;31:613–618.

• Crossref
• PubMed
Hauke RJ, Tarantolo SR. Hematopoietic growth factors. Lab Med 2000;31:613–618.10.1309/HNTM-ELUV-AV9G-MA1P)| false
• Search Google Scholar
• Export Citation

Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Support Cancer Ther 2003;1:23–35.

• Crossref
• PubMed
Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Support Cancer Ther 2003;1:23–35.10.3816/SCT.2003.n.00218628128)| false
• Search Google Scholar
• Export Citation

Lalami Y, Klastersky J. Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data. Crit Rev Oncol Hematol 2017;120:163–179.

• Crossref
• PubMed
Lalami Y, Klastersky J. Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data. Crit Rev Oncol Hematol 2017;120:163–179.2919833010.1016/j.critrevonc.2017.11.005)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. Implementation of the Biologics Price Competition and Innovation Act of 2009. Available at: https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/ucm215089.htm. Accessed March 18, 2019.

• PubMed
U.S. Food & Drug Administration. Implementation of the Biologics Price Competition and Innovation Act of 2009. Available at: https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/ucm215089.htm. Accessed March 18, 2019.)| false
• Export Citation

Lyman GH, Zon R, Harvey RD, et al.. Rationale, opportunities, and reality of biosimilar medications. N Engl J Med 2018;378:2036–2044.

• Crossref
• PubMed
Lyman GH, Zon R, Harvey RD, . Rationale, opportunities, and reality of biosimilar medications. N Engl J Med 2018;378:2036–2044.2979183210.1056/NEJMhle1800125)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. Biosimilar and Interchangeable Products. Available at: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580419.htm. Accessed February 28, 2019.

• PubMed
U.S. Food & Drug Administration. Biosimilar and Interchangeable Products. Available at: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580419.htm. Accessed February 28, 2019.)| false
• Search Google Scholar
• Export Citation

Awad M, Singh P, Hilas O. Zarxio (filgrastim-sndz): the first biosimilar approved by the FDA. P&T 2017;42:19–23.

• PubMed
Awad M, Singh P, Hilas O. Zarxio (filgrastim-sndz): the first biosimilar approved by the FDA. P&T 2017;42:19–23.)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. Filgrastim-sndz label information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125553lbl.pdf. Accessed October 9, 2019.

• PubMed
U.S. Food & Drug Administration. Filgrastim-sndz label information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125553lbl.pdf. Accessed October 9, 2019.31644052)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. Epoetin alfa-epbx label information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125545s000lbl.pdf. Accessed October 9, 2019.

• PubMed
U.S. Food & Drug Administration. Epoetin alfa-epbx label information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125545s000lbl.pdf. Accessed October 9, 2019.)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. Pegfilgrastim-jmdb label information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761075s000lbl.pdf. Accessed October 9, 2019.

• PubMed
U.S. Food & Drug Administration. Pegfilgrastim-jmdb label information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761075s000lbl.pdf. Accessed October 9, 2019.)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. Filgrastim-aafi label information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761080s000lbl.pdf. Accessed October 9, 2019.

• PubMed
U.S. Food & Drug Administration. Filgrastim-aafi label information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761080s000lbl.pdf. Accessed October 9, 2019.)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. Pegfilgrastim-cbqv label information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761039s000lbl.pdf. Accessed October 9, 2019.

• PubMed
U.S. Food & Drug Administration. Pegfilgrastim-cbqv label information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761039s000lbl.pdf. Accessed October 9, 2019.)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. Pegfilgrastim-bmez label information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761045lbl.pdf. Accessed November 8, 2019.

• PubMed
U.S. Food & Drug Administration. Pegfilgrastim-bmez label information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761045lbl.pdf. Accessed November 8, 2019.)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Available at: https://www.fda.gov/downloads/drugs/guidances/ucm291128.pdf. Accessed April 16, 2019.

• PubMed
U.S. Food & Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Available at: https://www.fda.gov/downloads/drugs/guidances/ucm291128.pdf. Accessed April 16, 2019.)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. Biosimilar Development, Review, and Approval. Available at: https://www.fda.gov/drugs/biosimilars/biosimilar-development-review-and-approval. Accessed April 16, 2019.

• PubMed
U.S. Food & Drug Administration. Biosimilar Development, Review, and Approval. Available at: https://www.fda.gov/drugs/biosimilars/biosimilar-development-review-and-approval. Accessed April 16, 2019.)| false
• Search Google Scholar
• Export Citation

Kleinberg M, Mosdell KW. Current and future considerations for the new classes of biologicals. Am J Health Syst Pharm 2004;61:695–708.

• Crossref
• PubMed
Kleinberg M, Mosdell KW. Current and future considerations for the new classes of biologicals. Am J Health Syst Pharm 2004;61:695–708.10.1093/ajhp/61.7.69515119576)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. FDA Medical Imaging Drugs Advisory Committee and the Oncologic Drugs Advisory Committee Briefing Materials. Tbo-filgrastim. Available at: https://wayback.archive-it.org/7993/20170405222000/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/MedicalImagingDrugsAdvisoryCommittee/UCM350157.pdf. Accessed January 18, 2019.

• PubMed
U.S. Food & Drug Administration. FDA Medical Imaging Drugs Advisory Committee and the Oncologic Drugs Advisory Committee Briefing Materials. Tbo-filgrastim. Available at: https://wayback.archive-it.org/7993/20170405222000/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/MedicalImagingDrugsAdvisoryCommittee/UCM350157.pdf. Accessed January 18, 2019.)| false
• Search Google Scholar
• Export Citation

Blackwell K, Gascon P, Krendyukov A, et al.. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol 2018;29:244–249.

• PubMed
Blackwell K, Gascon P, Krendyukov A, . Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol 2018;29:244–249.29091995)| false
• Search Google Scholar
• Export Citation

Sörgel F, Lerch H, Lauber T. Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product. BioDrugs 2010;24:347–357.

• Crossref
• PubMed
Sörgel F, Lerch H, Lauber T. Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product. BioDrugs 2010;24:347–357.2087387810.2165/11585100-000000000-00000)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. Oncologic Drugs Advisory Committee Meeting. BLA 125553. EP2006, a proposed biosimilar to Neupogen (filgrastim). Available at: https://wayback.archive-it.org/7993/20170405222922/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM428780.pdf. Accessed February 28, 2019.

• PubMed
U.S. Food & Drug Administration. Oncologic Drugs Advisory Committee Meeting. BLA 125553. EP2006, a proposed biosimilar to Neupogen (filgrastim). Available at: https://wayback.archive-it.org/7993/20170405222922/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM428780.pdf. Accessed February 28, 2019.)| false
• Search Google Scholar
• Export Citation

Mellstedt H. Anti-neoplastic biosimilars—the same rules as for cytotoxic generics cannot be applied. Ann Oncol 2013;24(Suppl 5):v23–28.

• Crossref
• PubMed
Mellstedt H. Anti-neoplastic biosimilars—the same rules as for cytotoxic generics cannot be applied. Ann Oncol 2013;24(Suppl 5):v23–28.10.1093/annonc/mdt32523975701)| false
• Search Google Scholar
• Export Citation

Harbeck N, Gascón P, Krendyukov A, et al.. Safety profile of biosimilar filgrastim (Zarzio/Zarxio): a combined analysis of phase III studies. Oncologist 2018;23:403–409.

• Crossref
• PubMed
Harbeck N, Gascón P, Krendyukov A, . Safety profile of biosimilar filgrastim (Zarzio/Zarxio): a combined analysis of phase III studies. Oncologist 2018;23:403–409.10.1634/theoncologist.2017-034829317553)| false
• Search Google Scholar
• Export Citation

Zecchini J, Yum K, Steinberg A, et al.. A single-center, retrospective analysis to compare the efficacy and safety of filgrastim-sndz to filgrastim for prophylaxis of chemotherapy-induced neutropenia and for neutrophil recovery following autologous stem cell transplantation. Support Care Cancer 2018;26:1013–1016.

• Crossref
• PubMed
Zecchini J, Yum K, Steinberg A, . A single-center, retrospective analysis to compare the efficacy and safety of filgrastim-sndz to filgrastim for prophylaxis of chemotherapy-induced neutropenia and for neutrophil recovery following autologous stem cell transplantation. Support Care Cancer 2018;26:1013–1016.2899012810.1007/s00520-017-3923-1)| false
• Search Google Scholar
• Export Citation

Schwartzberg LS, Lal LS, Balu S, et al.. Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar. Clinicoecon Outcomes Res 2018;10:493–500.

• Crossref
• PubMed
Schwartzberg LS, Lal LS, Balu S, . Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar. Clinicoecon Outcomes Res 2018;10:493–500.10.2147/CEOR.S168298)| false
• Search Google Scholar
• Export Citation

Schwartzberg LS, Lal LS, Balu S, et al.. Clinical outcomes of treatment with filgrastim versus a filgrastim biosimilar and febrile neutropenia-associated costs among patients with nonmyeloid cancer undergoing chemotherapy. J Manag Care Spec Pharm 2018;24:976–984.

• PubMed
Schwartzberg LS, Lal LS, Balu S, . Clinical outcomes of treatment with filgrastim versus a filgrastim biosimilar and febrile neutropenia-associated costs among patients with nonmyeloid cancer undergoing chemotherapy. J Manag Care Spec Pharm 2018;24:976–984.29687743)| false
• Search Google Scholar
• Export Citation

Chen X, Agiro A, Barron J, et al.. Early adoption of biosimilar growth factors in supportive cancer care. JAMA Oncol 2018;4:1779–1781.

• Crossref
• PubMed
Chen X, Agiro A, Barron J, . Early adoption of biosimilar growth factors in supportive cancer care. JAMA Oncol 2018;4:1779–1781.3038313510.1001/jamaoncol.2018.5090)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. Tbo-filgrastim label information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125294s0000lbl.pdf. Accessed January 18, 2019.

• PubMed
U.S. Food & Drug Administration. Tbo-filgrastim label information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125294s0000lbl.pdf. Accessed January 18, 2019.31644052)| false
• Search Google Scholar
• Export Citation

del Giglio A, Eniu A, Ganea-Motan D, et al.. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer 2008;8:332.

• Crossref
• PubMed
del Giglio A, Eniu A, Ganea-Motan D, . XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer 2008;8:332.10.1186/1471-2407-8-332)| false
• Search Google Scholar
• Export Citation

Engert A, Griskevicius L, Zyuzgin Y, et al.. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma 2009;50:374–379.

• Crossref
• PubMed
Engert A, Griskevicius L, Zyuzgin Y, . XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma 2009;50:374–379.1934772610.1080/10428190902756081)| false
• Search Google Scholar
• Export Citation

Gatzemeier U, Ciuleanu T, Dediu M, et al.. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol 2009;4:736–740.

• Crossref
• PubMed
Gatzemeier U, Ciuleanu T, Dediu M, . XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol 2009;4:736–740.10.1097/JTO.0b013e3181a5296419404210)| false
• Search Google Scholar
• Export Citation

Engert A, del Giglio A, Bias P, et al.. Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin’s lymphoma. Onkologie 2009;32:599–604.

• Crossref
• PubMed
Engert A, del Giglio A, Bias P, . Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin’s lymphoma. Onkologie 2009;32:599–604.1981607910.1159/000232580)| false
• Search Google Scholar
• Export Citation

Lubenau H, Bias P, Maly AK, et al.. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs 2009;23:43–51.

• Crossref
• PubMed
Lubenau H, Bias P, Maly AK, . Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs 2009;23:43–51.1934419110.2165/00063030-200923010-00005)| false
• Search Google Scholar
• Export Citation

Lubenau H, Sveikata A, Gumbrevicius G, et al.. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers. Int J Clin Pharmacol Ther 2009;47:275–282.

• Crossref
• PubMed
Lubenau H, Sveikata A, Gumbrevicius G, . Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers. Int J Clin Pharmacol Ther 2009;47:275–282.10.5414/CPP4727519356394)| false
• Search Google Scholar
• Export Citation

Zou L, Buchner A, Field JA, et al.. Immunogenicity assessment of tbo-filgrastim in cancer patients receiving chemotherapy. Bioanalysis 2018;10:1221–1228.

• Crossref
• PubMed
Zou L, Buchner A, Field JA, . Immunogenicity assessment of tbo-filgrastim in cancer patients receiving chemotherapy. Bioanalysis 2018;10:1221–1228.3005836310.4155/bio-2018-0071)| false
• Search Google Scholar
• Export Citation

The Center for Biosimilars. FDA approves second Neupogen biosimilar, Nivestym. Available at: https://www.centerforbiosimilars.com/news/fda-approves-second-neupogen-biosimilar-nivestym. Accessed February 28, 2019.

• PubMed
The Center for Biosimilars. FDA approves second Neupogen biosimilar, Nivestym. Available at: https://www.centerforbiosimilars.com/news/fda-approves-second-neupogen-biosimilar-nivestym. Accessed February 28, 2019.)| false
• Search Google Scholar
• Export Citation

Waller CF, Semiglazov VF, Tjulandin S, et al.. A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie 2010;33:504–511.

• PubMed
Waller CF, Semiglazov VF, Tjulandin S, . A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie 2010;33:504–511.20926897)| false
• Search Google Scholar
• Export Citation

Fruehauf S, Otremba B, Stötzer O, et al.. Compatibility of biosimilar filgrastim with cytotoxic chemotherapy during the treatment of malignant diseases (VENICE): a prospective, multicenter, non-interventional, longitudinal study. Adv Ther 2016;33:1983–2000.

• Crossref
• PubMed
Fruehauf S, Otremba B, Stötzer O, . Compatibility of biosimilar filgrastim with cytotoxic chemotherapy during the treatment of malignant diseases (VENICE): a prospective, multicenter, non-interventional, longitudinal study. Adv Ther 2016;33:1983–2000.2774335310.1007/s12325-016-0419-1)| false
• Search Google Scholar
• Export Citation

Brito M, Esteves S, André R, et al.. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study. Support Care Cancer 2016;24:597–603.

• Crossref
• PubMed
Brito M, Esteves S, André R, . Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study. Support Care Cancer 2016;24:597–603.2611195610.1007/s00520-015-2818-2)| false
• Search Google Scholar
• Export Citation

Frederic M, Stephane L, Didier K, et al.. Biosimilar filgrastim in the treatment and the prevention of chemotherapy-induced neutropenia: the next study [abstract]. J Geriatr Oncol 2014;5:S71. Abstract P100.

• PubMed
Frederic M, Stephane L, Didier K, . Biosimilar filgrastim in the treatment and the prevention of chemotherapy-induced neutropenia: the next study [abstract]. J Geriatr Oncol 2014;5:S71. Abstract P100.)| false
• Search Google Scholar
• Export Citation

Waller CF, Tiessen RG, Lawrence TE, et al.. A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim. J Cancer Res Clin Oncol 2018;144:1087–1095.

• Crossref
• PubMed
Waller CF, Tiessen RG, Lawrence TE, . A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim. J Cancer Res Clin Oncol 2018;144:1087–1095.10.1007/s00432-018-2643-329671069)| false
• Search Google Scholar
• Export Citation

Glaspy JA, O’Connor PG, Tang H, et al.. Randomized, single-blind, crossover study to assess the pharmacokinetic and pharmacodynamic bioequivalence of CHS-1701 to pegfilgrastim in healthy subjects [abstract]. J Clin Oncol 2017;35(Suppl):Abstract e21693.

• Crossref
• PubMed
Glaspy JA, O’Connor PG, Tang H, . Randomized, single-blind, crossover study to assess the pharmacokinetic and pharmacodynamic bioequivalence of CHS-1701 to pegfilgrastim in healthy subjects [abstract]. J Clin Oncol 2017;35(Suppl):Abstract e21693.10.1200/JCO.2017.35.15_suppl.e21693)| false
• Search Google Scholar
• Export Citation

O’Conner P, Tang H, Civoli F, et al.. Proposed pegfilgrastim biosimilar CHS-1701 demonstrates pharmacokinetic and pharmacodynamic similarity to marketed pegfilgrastim in a rat neutropenia model and in healthy subjects. Presented at the 22nd Congress of the European Hematology Association; June 22–25, 2017; Madrid, Spain. Abstract E1147.

• PubMed
O’Conner P, Tang H, Civoli F, . Proposed pegfilgrastim biosimilar CHS-1701 demonstrates pharmacokinetic and pharmacodynamic similarity to marketed pegfilgrastim in a rat neutropenia model and in healthy subjects. Presented at the 22nd Congress of the European Hematology Association; June 22–25, 2017; Madrid, Spain. Abstract E1147.)| false
• Export Citation

U.S. Food & Drug Administration. FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm609805.htm. Accessed February 28, 2019.

• PubMed
U.S. Food & Drug Administration. FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm609805.htm. Accessed February 28, 2019.)| false
• Search Google Scholar
• Export Citation

The Center for Biosimilars. FDA approves Coherus' pegfilgrastim biosimilar, Udenyca. Available at: https://www.centerforbiosimilars.com/news/fda-approves-coherus-pegfilgrastim-biosimilar-udenyca. Accessed February 4, 2019.

• PubMed
The Center for Biosimilars. FDA approves Coherus' pegfilgrastim biosimilar, Udenyca. Available at: https://www.centerforbiosimilars.com/news/fda-approves-coherus-pegfilgrastim-biosimilar-udenyca. Accessed February 4, 2019.)| false
• Search Google Scholar
• Export Citation

Hoy SM. Pegfilgrastim-jmdb/MYL-1401H: a pegfilgrastim biosimilar. BioDrugs 2019;33:117–120.

• Crossref
• PubMed
Hoy SM. Pegfilgrastim-jmdb/MYL-1401H: a pegfilgrastim biosimilar. BioDrugs 2019;33:117–120.3070141910.1007/s40259-019-00334-9)| false
• Search Google Scholar
• Export Citation

Sankaran PK, Palanivelu DV, Nair R, et al.. Characterization and similarity assessment of a pegfilgrastim biosimilar MYL-1401H. J Clin Oncol 2018;36(Suppl):e19028.

• Crossref
• PubMed
Sankaran PK, Palanivelu DV, Nair R, . Characterization and similarity assessment of a pegfilgrastim biosimilar MYL-1401H. J Clin Oncol 2018;36(Suppl):e19028.10.1200/JCO.2018.36.15_suppl.e19028)| false
• Search Google Scholar
• Export Citation

Waller CF, Ranganna GM, Pennella EJ, et al.. Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia. Ann Hematol 2019;98:1217–1224.

• Crossref
• PubMed
Waller CF, Ranganna GM, Pennella EJ, . Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia. Ann Hematol 2019;98:1217–1224.3082495610.1007/s00277-019-03639-5)| false
• Search Google Scholar
• Export Citation

Waller C, Ranganna GM, Pennella E, et al.. Comparison of immunogenicity between the proposed pegfilgrastim biosimilar MYL-1401H and reference pegfilgrastim. Blood 2017;130:3568.

• PubMed
Waller C, Ranganna GM, Pennella E, . Comparison of immunogenicity between the proposed pegfilgrastim biosimilar MYL-1401H and reference pegfilgrastim. Blood 2017;130:3568.)| false
• Search Google Scholar
• Export Citation

The Center for Biosimilars. FDA approves Sandoz's pegfilgrastim biosimilar, Ziextenzo. Available at: https://www.centerforbiosimilars.com/news/fda-approves-sandozs-pegfilgrastim-biosimilar-ziextenzo. Accessed November 8, 2019.

• PubMed
The Center for Biosimilars. FDA approves Sandoz's pegfilgrastim biosimilar, Ziextenzo. Available at: https://www.centerforbiosimilars.com/news/fda-approves-sandozs-pegfilgrastim-biosimilar-ziextenzo. Accessed November 8, 2019.)| false
• Search Google Scholar
• Export Citation

Nakov R, Gattu S, Wang J, et al.. Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects. Br J Clin Pharmacol 2018;84:2790–2801.

• Crossref
• PubMed
Nakov R, Gattu S, Wang J, . Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects. Br J Clin Pharmacol 2018;84:2790–2801.10.1111/bcp.1373130079636)| false
• Search Google Scholar
• Export Citation

Blackwell K, Donskih R, Jones CM, et al.. A comparison of proposed biosimilar LA-EP2006 and reference pegfilgrastim for the prevention of neutropenia in patients with early-stage breast cancer receiving myelosuppressive adjuvant or neoadjuvant chemotherapy: pegfilgrastim randomized oncology (supportive care) trial to evaluate comparative treatment (PROTECT-2), a phase III, randomized, double-blind trial. Oncologist 2016;21:789–794.

• PubMed
Blackwell K, Donskih R, Jones CM, . A comparison of proposed biosimilar LA-EP2006 and reference pegfilgrastim for the prevention of neutropenia in patients with early-stage breast cancer receiving myelosuppressive adjuvant or neoadjuvant chemotherapy: pegfilgrastim randomized oncology (supportive care) trial to evaluate comparative treatment (PROTECT-2), a phase III, randomized, double-blind trial. Oncologist 2016;21:789–794.27091420)| false
• Search Google Scholar
• Export Citation

Harbeck N, Lipatov O, Frolova M, et al.. Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. Future Oncol 2016;12:1359–1367.

• Crossref
• PubMed
Harbeck N, Lipatov O, Frolova M, . Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. Future Oncol 2016;12:1359–1367.2702017010.2217/fon-2016-0016)| false
• Search Google Scholar
• Export Citation

Harbeck N, Wang J, Otto GP, et al.. Safety analysis of proposed pegfilgrastim biosimilar in phase I and phase III studies. Future Oncol 2019;15:1313–1322.

• Crossref
• PubMed
Harbeck N, Wang J, Otto GP, . Safety analysis of proposed pegfilgrastim biosimilar in phase I and phase III studies. Future Oncol 2019;15:1313–1322.10.2217/fon-2018-087830834780)| false
• Search Google Scholar
• Export Citation

Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004;116(Suppl 7A)11S–26S.

• Crossref
• PubMed
Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004;116(Suppl 7A)11S–26S.10.1016/j.amjmed.2003.12.008)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. FDA approves first epoetin alfa biosimilar for the treatment of anemia. Available at: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm607703.htm. Accessed February 28, 2019.

• PubMed
U.S. Food & Drug Administration. FDA approves first epoetin alfa biosimilar for the treatment of anemia. Available at: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm607703.htm. Accessed February 28, 2019.)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. FDA Oncologic Drugs Advisory Committee Briefing Materials: ‟Epoetin Hospira,” a proposed biosimilar to US-licensed Epogen/Procrit. Available at: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM561560.pdf. Accessed July 10, 2018.

• PubMed
U.S. Food & Drug Administration. FDA Oncologic Drugs Advisory Committee Briefing Materials: ‟Epoetin Hospira,” a proposed biosimilar to US-licensed Epogen/Procrit. Available at: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM561560.pdf. Accessed July 10, 2018.)| false
• Search Google Scholar
• Export Citation

Fishbane S, Singh B, Kumbhat S, et al.. Intravenous epoetin alfa-epbx versus epoetin alfa for treatment of anemia in end-stage kidney disease. Clin J Am Soc Nephrol 2018;13:1204–1214.

• Crossref
• PubMed
Fishbane S, Singh B, Kumbhat S, . Intravenous epoetin alfa-epbx versus epoetin alfa for treatment of anemia in end-stage kidney disease. Clin J Am Soc Nephrol 2018;13:1204–1214.2992173410.2215/CJN.11631017)| false
• Search Google Scholar
• Export Citation

Thadhani R, Guilatco R, Hymes J, et al.. Switching from epoetin alfa (Epogen(R)) to epoetin alfa-epbx (RetacritTM) using a specified dosing algorithm: a randomized, non-inferiority study in adults on hemodialysis. Am J Nephrol 2018;48:214–224.

• Crossref
• PubMed
Thadhani R, Guilatco R, Hymes J, . Switching from epoetin alfa (Epogen(R)) to epoetin alfa-epbx (RetacritTM) using a specified dosing algorithm: a randomized, non-inferiority study in adults on hemodialysis. Am J Nephrol 2018;48:214–224.10.1159/00049262130196301)| false
• Search Google Scholar
• Export Citation

Kosaka Y, Rai Y, Masuda N, et al.. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer 2015;23:1137–1143.

• Crossref
• PubMed
Kosaka Y, Rai Y, Masuda N, . Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer 2015;23:1137–1143.2557643310.1007/s00520-014-2597-1)| false
• Search Google Scholar
• Export Citation

Kuderer NM, Dale DC, Crawford J, et al.. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158–3167.

• Crossref
• PubMed
Kuderer NM, Dale DC, Crawford J, . Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158–3167.1763449610.1200/JCO.2006.08.8823)| false
• Search Google Scholar
• Export Citation

Lyman GH, Kuderer NM, Crawford J, et al.. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011;117:1917–1927.

• Crossref
• PubMed
Lyman GH, Kuderer NM, Crawford J, . Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011;117:1917–1927.2150976910.1002/cncr.25691)| false
• Search Google Scholar
• Export Citation

Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 2014;90:190–199.

• Crossref
• PubMed
Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 2014;90:190–199.10.1016/j.critrevonc.2013.12.00624434034)| false
• Search Google Scholar
• Export Citation

Lyman GH, Poniewierski MS. A patient risk model of chemotherapy-induced febrile neutropenia: lessons learned from the ANC study group. J Natl Compr Canc Netw 2017;15:1543–1550.

• Crossref
• PubMed
Lyman GH, Poniewierski MS. A patient risk model of chemotherapy-induced febrile neutropenia: lessons learned from the ANC study group. J Natl Compr Canc Netw 2017;15:1543–1550.10.6004/jnccn.2017.7038)| false
• Search Google Scholar
• Export Citation

Weycker D, Li X, Tzivelekis S, et al.. Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. Support Care Cancer 2017;25:439–447.

• Crossref
• PubMed
Weycker D, Li X, Tzivelekis S, . Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. Support Care Cancer 2017;25:439–447.10.1007/s00520-016-3421-x27734153)| false
• Search Google Scholar
• Export Citation

Lyman GH, Allcott K, Garcia J, et al.. The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review. Support Care Cancer 2017;25:2619–2629.

• Crossref
• PubMed
Lyman GH, Allcott K, Garcia J, . The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review. Support Care Cancer 2017;25:2619–2629.2848488210.1007/s00520-017-3703-y)| false
• Search Google Scholar
• Export Citation

Meropol NJ, Miller LL, Korn EL, et al.. Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 1992;84:1201–1203.

• Crossref
• PubMed
Meropol NJ, Miller LL, Korn EL, . Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 1992;84:1201–1203.137890510.1093/jnci/84.15.1201)| false
• Search Google Scholar
• Export Citation

American Society of Clinical Oncology. Letter to CMS regarding “Neulasta administered same day as chemotherapy”. Available at: http://www.asco.org/sites/default/files/letter_to_cms_rac_audit_on_neulasta_110912_lthd.pdf. Accessed February 28, 2019.

• PubMed
American Society of Clinical Oncology. Letter to CMS regarding “Neulasta administered same day as chemotherapy”. Available at: http://www.asco.org/sites/default/files/letter_to_cms_rac_audit_on_neulasta_110912_lthd.pdf. Accessed February 28, 2019.)| false
• Export Citation

Yang BB, Morrow PK, Wu X, et al.. Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. Cancer Chemother Pharmacol 2015;75:1199–1206.

• Crossref
• PubMed
Yang BB, Morrow PK, Wu X, . Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. Cancer Chemother Pharmacol 2015;75:1199–1206.2589471910.1007/s00280-015-2731-x)| false
• Search Google Scholar
• Export Citation

Green MD, Koelbl H, Baselga J, et al.. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29–35.

• Crossref
• PubMed
Green MD, Koelbl H, Baselga J, . A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29–35.10.1093/annonc/mdg01912488289)| false
• Search Google Scholar
• Export Citation

Vogel CL, Wojtukiewicz MZ, Carroll RR, et al.. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178–1184.

• Crossref
• PubMed
Vogel CL, Wojtukiewicz MZ, Carroll RR, . First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178–1184.1571831410.1200/JCO.2005.09.102)| false
• Search Google Scholar
• Export Citation

Watanabe T, Tobinai K, Shibata T, et al.. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin’s lymphoma: JCOG 0203 trial. J Clin Oncol 2011;29:3990–3998.

• Crossref
• PubMed
Watanabe T, Tobinai K, Shibata T, . Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin’s lymphoma: JCOG 0203 trial. J Clin Oncol 2011;29:3990–3998.10.1200/JCO.2011.34.850821931035)| false
• Search Google Scholar
• Export Citation

Hecht JR, Pillai M, Gollard R, et al.. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer 2010;9:95–101.

• Crossref
• PubMed
Hecht JR, Pillai M, Gollard R, . A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer 2010;9:95–101.10.3816/CCC.2010.n.01320378503)| false
• Search Google Scholar
• Export Citation

Brusamolino E, Rusconi C, Montalbetti L, et al.. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006;91:496–502.

• PubMed
Brusamolino E, Rusconi C, Montalbetti L, . Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006;91:496–502.16537117)| false
• Search Google Scholar
• Export Citation

Burstein HJ, Parker LM, Keshaviah A, et al.. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 2005;23:8340–8347.

• Crossref
• PubMed
Burstein HJ, Parker LM, Keshaviah A, . Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 2005;23:8340–8347.10.1200/JCO.2005.02.862116293865)| false
• Search Google Scholar
• Export Citation

Jones RL, Walsh G, Ashley S, et al.. A randomised pilot phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. Br J Cancer 2009;100:305–310.

• Crossref
• PubMed
Jones RL, Walsh G, Ashley S, . A randomised pilot phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. Br J Cancer 2009;100:305–310.10.1038/sj.bjc.660486219165198)| false
• Search Google Scholar
• Export Citation

Pirker R, Ulsperger E, Messner J, et al.. Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer. Hai 2006;184:279–285.

• PubMed
Pirker R, Ulsperger E, Messner J, . Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer. Hai 2006;184:279–285.)| false
• Search Google Scholar
• Export Citation

Estcourt LJ, Stanworth SJ, Hopewell S, et al.. Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev 2016;4:CD005339.

• PubMed
Estcourt LJ, Stanworth SJ, Hopewell S, . Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev 2016;4:CD005339.27128488)| false
• Search Google Scholar
• Export Citation

Clark OA, Lyman GH, Castro AA, et al.. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005;23:4198–4214.

• Crossref
• PubMed
Clark OA, Lyman GH, Castro AA, . Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005;23:4198–4214.10.1200/JCO.2005.05.64515961767)| false
• Search Google Scholar
• Export Citation

Johnston E, Crawford J, Blackwell S, et al.. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522–2528.

• Crossref
• PubMed
Johnston E, Crawford J, Blackwell S, . Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522–2528.10.1200/JCO.2000.18.13.252210893282)| false
• Search Google Scholar
• Export Citation

Lyman GH, Balaban E, Diaz M, et al.. American Society of Clinical Oncology statement: biosimilars in oncology. J Clin Oncol 2018;36:1260–1265.

• Crossref
• PubMed
Lyman GH, Balaban E, Diaz M, . American Society of Clinical Oncology statement: biosimilars in oncology. J Clin Oncol 2018;36:1260–1265.10.1200/JCO.2017.77.4893)| false
• Search Google Scholar
• Export Citation